| scholarly article | Q13442814 |
| P50 | author | Masatoshi Kudo | Q40473885 |
| P2093 | author name string | K Nakajima | |
| T Takayama | |||
| J A Marrero | |||
| A J Sanyal | |||
| L Dagher | |||
| J Furuse | |||
| J-P Bronowicki | |||
| J F Geschwind | |||
| C Papandreou | |||
| R Lencioni | |||
| S K Yoon | |||
| X-P Chen | |||
| S-L Ye | |||
| L Ladrón de Guevara | |||
| S Heldner | |||
| F Cihon | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study | Q34001687 | ||
| Hepatocellular Carcinoma: Consensus Recommendations of the National Cancer Institute Clinical Trials Planning Meeting | Q34131801 | ||
| The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective | Q34625481 | ||
| Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. | Q36476765 | ||
| Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies | Q37263149 | ||
| Loco-regional treatment of hepatocellular carcinoma | Q37766546 | ||
| The etiology of hepatocellular carcinoma and consequences for treatment | Q37813313 | ||
| Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies | Q37828640 | ||
| Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib | Q43124491 | ||
| Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. | Q46183882 | ||
| P2507 | corrigendum / erratum | Erratum | Q57763113 |
| P433 | issue | 7 | |
| P304 | page(s) | 675-683 | |
| P577 | publication date | 2012-07-01 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study | |
| P478 | volume | 66 |
| Q37399436 | A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma |
| Q61811584 | A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015 |
| Q38639762 | Chemotherapy for hepatocellular carcinoma: The present and the future |
| Q38217457 | Combination of intra-arterial therapies and sorafenib: is there a clinical benefit? |
| Q35776357 | Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy |
| Q35419331 | Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction |
| Q35091836 | Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study |
| Q40846805 | Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma |
| Q40729549 | Current chemotherapies for advanced hepatocellular carcinoma |
| Q38408866 | Diagnosis and treatment of hepatocellular carcinoma: An update |
| Q34467228 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. |
| Q57763113 | Erratum |
| Q35739362 | Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma |
| Q36325065 | Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data |
| Q33411001 | Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma |
| Q34693220 | GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis |
| Q26783881 | Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols |
| Q35631295 | Hong Kong consensus recommendations on the management of hepatocellular carcinoma |
| Q36257073 | Impact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients |
| Q38986591 | Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study |
| Q37640588 | In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. |
| Q36028682 | Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma |
| Q26996578 | Management of hepatocellular carcinoma with portal vein thrombosis |
| Q33666679 | Multidisciplinary management of hepatocellular carcinoma in clinical practice |
| Q26825172 | Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update |
| Q37578521 | Nonsurgical treatment for localized hepatocellular carcinoma. |
| Q48722303 | Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study |
| Q33443438 | Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. |
| Q35838170 | Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. |
| Q26863748 | Recent advances in multidisciplinary management of hepatocellular carcinoma |
| Q39979280 | Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study |
| Q33948042 | Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma |
| Q37696388 | Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma |
| Q34728237 | Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. |
| Q37433645 | Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. |
| Q40741225 | Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma |
| Q36916295 | Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. |
| Q52676764 | Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study. |
| Q30486078 | Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit |
| Q34263363 | Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma |
| Q38830457 | Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. |
| Q50063114 | Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks |
| Q41725545 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors |
| Q87226010 | Sorafenib use in hepatocellular carcinoma: more questions than answers |
| Q38544841 | Sorafenib: 10 years after the first pivotal trial. |
| Q39181337 | Sorafenib: A Review in Hepatocellular Carcinoma |
| Q39458547 | Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. |
| Q35888783 | The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. |
| Q34826535 | The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations |
| Q36508942 | The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. |
| Q26772299 | Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review |
| Q30376269 | Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis |
| Q36682439 | Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry |
| Q92628462 | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) |
| Q39149264 | Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma |
| Q53324924 | Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. |
| Q57763113 | Erratum | main subject | P921 |
Search more.